M 6620

Drug Profile

M 6620

Alternative Names: Captisol® enabled VX 970; M6620; VX-970

Latest Information Update: 11 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer Merck KGaA; National Cancer Institute (USA)
  • Class Antineoplastics
  • Mechanism of Action ATR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Urogenital cancer
  • Phase I/II Small cell lung cancer; Solid tumours
  • Phase I Breast cancer; Non-small cell lung cancer
  • Preclinical Acute myeloid leukaemia

Most Recent Events

  • 13 Oct 2017 Merck KGaA plans a rollover phase I trial for Solid tumours (Late-stage disease, Monotherapy, Combination therapy) in Germany (IV) (NCT03309150)
  • 08 Sep 2017 Initial efficacy and adverse events data from a phase I trial in Breast cancer presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 11 Jan 2017 VX 970 licensed to Merck KGaA worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top